Parkinson's Disease Trial, Recruiting NCT07083089 Sponsor: Cilcare SAS Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT07083089
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 50 and 85 years old.
  • You are fluent in French as your native language.
  • The trial investigator considers you reliable and able to follow the study requirements, in good general health, and able to travel to appointments.
  • You are covered by French public health insurance (Sécurité Sociale).
  • You are willing to sign a consent form agreeing to take part.

If you have mild memory problems (amnestic MCI):

  • You have been diagnosed with a specific type of mild cognitive impairment that mainly affects memory, confirmed by standard memory tests showing scores within a particular range (confirm with trial site).

If you have Parkinson's disease:

  • You have a confirmed diagnosis of Parkinson's disease with specific movement symptoms such as slowness, tremor at rest, or muscle stiffness, and your cognitive score is within an acceptable range (confirm with trial site).

If you are joining as a healthy volunteer (control):

  • You have no diagnosis of a neurological condition such as Parkinson's disease or memory impairment, and your cognitive test score is in the normal range (confirm with trial site).

Who may not be able to join:

  • You have a known ear condition that affects how sound is conducted through the ear, such as otosclerosis, a problem with the eardrum or ear bones, Ménière's disease-related hearing loss, ear infections, or were born with deafness.
  • You have a psychiatric illness not related to a neurological or degenerative condition.
  • You have a neurological or blood vessel condition in the brain, such as a stroke, epilepsy, or dementia.
  • You have movement difficulties that could interfere with hearing tests.
  • You have been diagnosed with type 2 diabetes.
  • You have a problem with alcohol or drug addiction.
  • You have a cochlear implant (an electronic hearing device surgically placed in the ear).
  • You are currently taking, or have recently taken, certain medications known to potentially harm hearing, including: some antibiotics (aminoglycosides by injection, macrolides, or tetracyclines in the last 15 days); certain malaria treatments (quinine, hydroxychloroquine, or chloroquine in the last 15 days); platinum-based chemotherapy at any point in the past; high doses of loop diuretics like furosemide (above 60mg/day by mouth); or high doses of salicylate medicines (low-dose aspirin up to 320mg/day is allowed) (confirm with trial site).
  • You have had surgery on your ear in the past.
  • You are currently pregnant or breastfeeding.
  • You are legally protected or unable to give your own consent to participate.
  • You are already taking part in another clinical study that could affect the results of this one.

You may also be excluded after your second visit if:

  • Less than 90% of your eardrum can be seen during an ear examination (for example, due to earwax buildup or a perforated eardrum).
  • Hearing tests show a specific type of hearing loss related to sound conduction through the ear.
  • Your eardrum pressure test (tympanogram) gives an abnormal result.
  • There is a significant difference in hearing ability between your two ears — more than 15 dB difference (applies to MCI patients and healthy volunteers only).
  • You have complete hearing loss in one ear.
  • You have profound hearing loss in both ears (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mathieu SCHUE, PhD, Cilcare SAS

Phone: +33769042226

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Cilcare SAS
Registry
ClinicalTrials.gov
Start date
24 March 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Prevalence of hidden hearing loss

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov